We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Guerbet (GBT) EUR1

Sell:€38.50 Buy:€40.00 Change: €0.65 (1.64%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: €0.65 (1.64%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
Change: €0.65 (1.64%)
Market closed |  Prices as at close on 19 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.

Contact details

15 rue des Vanesses, Zone Paris Nord II
+33 (1) 45915000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€501.22 million
Shares in issue:
12.62 million
Health Care Supplies
Euronext Paris

Key personnel

  • David Hale
    Chairman of the Executive Committee, Chief Executive Officer
  • Jerome Estampes
    Chief Financial Officer, Senior Vice President - IT and Business Development and Licensing, Member of the Executive Committee
  • Charlotte Bamiere
    Senior Vice President - Compliance, General Counsel, Member of the Executive Committee
  • Valerie Brissart
    Senior Vice President - Marketing - Diagnostic Imaging, Member of the Executive Committee
  • Eva Ohlsson
    Senior Vice President - Human Resources, Member of the Executive Committee
  • Christine Allard
    Senior Vice President - Public Affairs and Corporate Communications, Member of the Executive Committee
  • Raoul Bernhardt
    Senior Vice President - Industrial Operations, EHS and Procurement, Member of the Executive Committee
  • Philippe Bourrinet
    Senior Vice President - Development, Medical and Regulatory Affairs and Group Responsible Pharmacist, Member of the Executive Committee
  • Francois Nicolas
    Senior Vice President - Research, Development, Innovation and AI, Member of the Executive Committee
  • Dan Raffi
    Senior Vice President - Commercial Operations, Member of the Executive Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.